Dr. Öğr. Üyesi Tarık Ercan

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: medicalpark.com.tr.

Experience

• 20112012 Van Bölge Eğitim ve Araşlıkma Hastanesi Acil Servismedicalpark.com.tr
• 20122017 Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi İç Hastalıkları Asistanmedicalpark.com.tr
• 20172018 Nusaybin Devlet Hastanesi İç Hastalıkları Uzmanımedicalpark.com.tr
• Experience2018 Okmeydanı Eğitim ve Araştırma Hastanesi İç Hastalıkları Uzmanımedicalpark.com.tr
• 20182022 Marmara Üniversitesi Tıp Fakültesi Yandal Asistanmedicalpark.com.tr
• 20222023 Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Hematoloji Uzmanımedicalpark.com.tr

Education

• Education2011 Yüzüncü Yıl Üniversitesi Tıp Fakültesimedicalpark.com.tr
• 20122016 Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi İç Hastalıklarımedicalpark.com.tr
• 20182021 Marmara Üniversitesi Tıp Fakültesimedicalpark.com.tr

• SpecialtyHaematologymedicalpark.com.trFrom source
• Department name at the sourceHematoloji Polikliniğimedicalpark.com.trFrom source
• InstitutionMedical Park Göztepemedicalpark.com.trFrom source
• Publications16 publicationsORCID, OpenAlexFrom source
• ORCID0000-0003-4037-4106ORCIDFrom source
• Last synchronised4 November 2026 20:38https://www.medicalpark.com.tr/hekimler/tarik-ercanmedicalpark.com.tr

1. Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort

   Medicina, 2026

   DOI 10.3390/medicina62040736 PMID 42075610 Open-access full textSource: ORCID

2. Polycythemia Vera in Clinical Practice: A Single-Center Experience Focusing on Thrombotic Complications and Management Strategies

   Indian Journal of Hematology and Blood Transfusion, 2026

   DOI 10.1007/s12288-026-02400-z Source: OpenAlex

3. Prediction of CD34+ hematopoietic stem cells in healthy allogeneic stem cell donors on the Optia cell separator based on CE2: Which formula is more correlated with actual CD34+?

   Transfusion, 2024

   DOI 10.1111/trf.17990 PMID 39152946 7 citations (Europe PMC) Open-access full textSource: ORCID

4. Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients,Esansiyel Trombositemide CALR ve JAK2V617F Mutasyonlarının Klinik Seyir ve Hastalık Sonuçlarına Etkisi: Türk Hastalarda Geriye Dönük Çok Merkezli Çalışma

   Turkish Journal of Hematology, 2024

   DOI 10.4274/tjh.galenos.2024.2023.0430 PMID 38433449 10 citations (Europe PMC) Open-access full textSource: ORCID

5. PB2147: CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE

   HemaSphere, 2023

   DOI 10.1097/01.hs9.0000975348.60378.b8 Open-access full textSource: OpenAlex

6. P-055 Clinical factors determining the survival of multiple myeloma patients with extramedullary disease: a single-center experience

   Clinical Lymphoma Myeloma & Leukemia, 2023

   DOI 10.1016/s2152-2650(23)01673-7 Source: OpenAlex

7. Impact of autologous stem cell transplantation on survival outcomes in patients with peripheral T cell lymphoma.

   Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2022

   DOI 10.1016/j.transci.2022.103514 PMID 35934613 Source: ORCID

8. Real-life ruxolitinib experience in intermediate-risk myelofibrosis.

   Blood research, 2021

   DOI 10.5045/br.2021.2021101 PMID 34916339 6 citations (Europe PMC) Open-access full textSource: ORCID

9. APLASTİK ANEMİ HASTALARINDA ELTROMBOPAG DENEYİMİ: TÜRKİYE ÇOK MERKEZLİ GERÇEK YAŞAM VERİSİ

   Kocaeli Üniversitesi - AVESİS, 2021

   Source: OpenAlex

10. TEDAVİ NAİF VE NÜKS/REFRAKTER KLL HASTALARINDAOBİNİTUZUMAB DENEYİMİ: TÜRKİYE ÇOK MERKEZLİGERÇEK YAŞAM VERİSİ

    Kocaeli Üniversitesi - AVESİS, 2021

    Source: OpenAlex